Radius Health Publishes Investor Presentation Outlining Company’s Progress and Board Process Resulting in Agreement to be Acquired at Significant Premium
07 Julio 2022 - 5:30PM
Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS)
today published a detailed investor presentation available at:
https://ir.radiuspharm.com/events-and-presentations/.
The document discusses the Company’s progress since 2020 and
also outlines the comprehensive strategic review process conducted
by the Radius Board of Directors, which resulted in its unanimous
approval of the Company’s acquisition by Gurnet Point Capital and
Patient Square Capital at a significant premium.
Stockholders are urged to vote “FOR” all three of the Company’s
highly qualified, independent nominees on the BLUE proxy card at
its upcoming Annual Meeting of Stockholders, which will be held
online on July 26, 2022.
YOUR VOTE IS
IMPORTANTVOTE “FOR” RADIUS’ THREE NOMINEES ON
THE BLUE PROXY CARD
TODAY
509 Madison AvenueNew York, NY 10022Email:
RDUS@info.morrowsodali.comCall toll-free at (800) 662-5200 (in
North America)or +1 (203) 658-9400 (outside of North America)
About Radius Radius is a global
biopharmaceutical company focused on addressing unmet medical needs
in the areas of bone health, neuro- orphan diseases, and oncology.
Radius’ lead product, TYMLOS® (abaloparatide) injection, was
approved by the U.S. Food and Drug Administration for the treatment
of postmenopausal women with osteoporosis at high risk for
fracture. The Radius clinical pipeline includes investigational
abaloparatide injection for potential use in the treatment of men
with osteoporosis; the investigational drug, elacestrant (RAD1901),
for potential use in the treatment of hormone-receptor positive
breast cancer out-licensed to Menarini Group; and the
investigational drug RAD011, a synthetic cannabidiol oral solution
with potential utilization in multiple neuro-endocrine,
neurodevelopmental, or neuropsychiatric disease areas, initially
targeting Prader-Willi syndrome, Angelman syndrome, and infantile
spasms.
Forward-Looking StatementsThis communication
contains forward-looking statements, including the ability of the
parties to complete the transactions contemplated by the Agreement
and Plan of Merger (the “Merger Agreement”) by and among Radius
Health, Inc. (the “Company”), Ginger Acquisition, Inc., a Delaware
corporation (“Parent”), a subsidiary jointly owned by Gurnet Point
and Patient Square, and Ginger Merger Sub, Inc., a Delaware
corporation and wholly owned subsidiary of Parent (“Purchaser”),
including the parties’ ability to satisfy the conditions to the
consummation of the tender offer (the “Offer”) to purchase each
issued and outstanding share (the “Shares”) of common stock, par
value $0.0001 per share, of the Company contemplated thereby and
the other conditions set forth in the Merger Agreement, statements
about the expected timetable for completing the transactions and
statements about potential benefits of the transactions for the
Company. These statements are neither promises nor guarantees, and
are subject to known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, the
following: uncertainties as to the timing of the offer and the
subsequent merger of Purchaser with and into the Company (the
“Merger”); uncertainties as to how many of the Shares will be
tendered in the Offer; the possibility that various conditions to
the consummation of the Offer and the Merger may not be satisfied
or waived; the effects of disruption from the transactions
contemplated by the Merger Agreement and the impact of the
announcement and pendency of the transactions on the Company’s
business; the risk that stockholder litigation in connection with
the Offer or the Merger may result in significant costs of defense,
indemnification and liability; the risks related to non-achievement
of the contingent value right (“CVR”) milestone and that holders of
the CVRs will not receive payments in respect of the CVRs; the
adverse impact the ongoing COVID-19 pandemic is having and is
expected to continue to have on the Company’s business, financial
condition and results of operations, including our commercial
operations and sales, clinical trials, preclinical studies, and
employees; quarterly fluctuation in the Company’s financial
results; the Company’s dependence on the success of TYMLOS, and the
Company’s inability to ensure that TYMLOS will obtain regulatory
approval outside the U.S. or be successfully commercialized in any
market in which it is approved; risks related to manufacturing,
supply and distribution; and the risk of litigation or other
challenges regarding our intellectual property rights. These and
other important risks and uncertainties discussed in the Company’s
filings with the SEC, including under the caption “Risk Factors” in
the Company’s Annual Report on Form 10-K for the year ending
December 31, 2021, and subsequent filings with the Securities and
Exchange Commission (“SEC”), could cause actual results to differ
materially from those indicated by the forward-looking statements
made in this communication. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and the Company
assumes no obligation to, and does not intend to, update or revise
these forward-looking statements, whether as a result of new
information, future events, or otherwise, unless required by law.
The Company does not give any assurance that it will achieve its
expectations.
Additional Information and Where to Find It
The Offer for the outstanding Shares referenced in this
presentation has not yet commenced. This communication is for
informational purposes only and is neither an offer to purchase nor
a solicitation of an offer to sell securities, nor is it a
substitute for the tender offer materials that Parent and Purchaser
will file with the SEC, upon the commencement of the Offer. At the
time the Offer is commenced, Parent and its acquisition subsidiary
will file a tender offer statement on Schedule TO, including an
offer to purchase, a letter of transmittal and related documents,
and thereafter the Company will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC with respect to the Offer.
THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A
LETTER OF TRANSMITTAL AND RELATED DOCUMENTS) AND THE
SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 WILL
CONTAIN IMPORTANT INFORMATION. THE COMPANY’S STOCKHOLDERS ARE URGED
TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AS
EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY
WILL CONTAIN IMPORTANT INFORMATION THAT HOLDERS OF THE COMPANY’S
SECURITIES SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING
TENDERING THEIR SECURITIES. Holders of Shares can obtain these
documents free of charge when they are filed from the SEC’s website
at www.sec.gov or on the Company’s website at
www.radiuspharm.com.
Investor Contact
Ethan
HoldawayEmail: investor-relations@radiuspharm.comPhone: (617)
583-2017
Media Contact
Dan Gagnier / Jeffrey MathewsGagnier CommunicationsEmail:
radius@gagnierfc.comPhone: (646) 569-5897
Radius Recycling (NASDAQ:RDUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Radius Recycling (NASDAQ:RDUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024